25 completed, 10 terminated, 6 active not recruiting, 3 recruiting. 27 Phase 2, 24 Phase 1, 5 Phase 3, 1 Early Phase 1.
Follow talimogene laherparepvec: new trials by email Literature Review of talimogene laherparepvec trials Research Report on talimogene laherparepvec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 Imlygic - NF1, Neurofibromatosis | Phase 1 | Recruiting | Johns Hopkins University | 10 | 2026-02-01 | 2026-05-08 |
| Neoadjuvant Intralesional Injection of Talimogene Laherparepvec Talimogene Laherparepvec, Neoadjuvant Radiation, Surgery - Soft Tissue Sarcoma, Sarcoma,Soft Tissue | Phase 2 | Active not recruiting | John Rieth | 2 | 2025-03-03 | 2026-07-17 |
| Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma Talimogene laherparepvec - Kaposi Sarcoma | Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 20 | 2021-01-01 | 2022-06-10 |
| TVEC and Preop Radiation for Sarcoma (8 ml Dose) Talimogene Laherparepvec, Radiotherapy - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Active not recruiting | John Rieth | 8 | 2020-09-10 | 2026-01-29 |
| Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease T-VEC - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Completed | The Netherlands Cancer Institute | 24 | 2020-09-08 | 2025-03-12 |
| Neoadjuvant T-VEC in High Risk Early Melanoma T-Vec - Melanoma | Phase 2 | Suspended | University of California, Davis | 6 | 2020-05-21 | 2023-09-15 |
| T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer Anastrozole, Exemestane, Fulvestrant - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Completed | University of California, San Francisco | 20 | 2020-02-05 | 2025-05-21 |
| Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Panitumumab, Talimogene Laherparepvec - Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma | Phase 1 | Terminated | Rutgers, The State University of New Jersey | 5 | 2020-01-31 | 2026-01-23 |
| Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). Talimogene laherparepvec, Pembrolizumab - Melanoma | Phase 2 | Completed | Amgen | 72 | 2020-01-22 | 2025-01-07 |
| Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging - Leiomyosarcoma, Liposarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2019-12-31 | 2026-09-25 |
| Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma T-VEC - Angiosarcoma of Skin | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 5 | 2019-08-20 | 2022-11-01 |
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Ipilimumab, Nivolumab, Talimogene Laherparepvec - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2019-07-10 | 2023-08-15 |
| Neoadjuvant Combination Immunotherapy for Stage III Melanoma Pembrolizumab, Talimogene Laherparepvec - Cutaneous Melanoma | Phase 2 | Recruiting | University of Louisville | 28 | 2019-07-03 | 2024-05-02 |
| Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor) - Melanoma (Skin), Melanoma Stage IIIb-IVM1a | Phase 2 | Withdrawn | TriHealth Inc. | 2019-06-24 | 2020-10-19 | |
| Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies Talimogene Laherparepvec - Peritoneal Surface Malignancy | Phase 1 | Completed | Dan Blazer III, M.D. | 28 | 2019-05-23 | 2024-11-20 |
| Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC], Nivolumab IV Soln 100 MG/10ML, Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution - Sarcoma | Phase 2 | Recruiting | Sarcoma Oncology Research Center, LLC | 200 | 2019-05-15 | 2025-02-24 |
| Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer Capecitabine, Fluorouracil, Leucovorin - Locally Advanced Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 3 | 2019-05-14 | 2024-05-23 |
| A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion Talimogene laherparepvec (TVEC), Nivolumab - Malignant Pleural Effusion, Stage IV Metastatic Cancer | Phase 1 / Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 1 | 2019-03-06 | 2021-04-20 |
| Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer Talimogene laherparepvec, Atezolizumab - Breast Cancer | Early Phase 1 | Completed | SOLTI Breast Cancer Research Group | 28 | 2018-12-10 | 2025-09-09 |
| Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) CD1c (BDCA-1)+ myDC - Melanoma | Phase 1 | Unknown | Universitair Ziekenhuis Brussel | 18 | 2018-09-28 | 2020-12-29 |
Showing 20 of 52. Sign in to see all of them.
Melanoma (22) · Sarcoma (8) · Breast Neoplasms (5) · Carcinoma, Merkel Cell (4) · Carcinoma, Squamous Cell (3) · Neoplasm Metastasis (3) · Triple Negative Breast Neoplasms (3) · Carcinoma, Basal Cell (2) · Lymphoma, T-Cell, Cutaneous (2) · Mycosis Fungoides (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Papillary (1) · Breast Carcinoma In Situ (1) · Carcinoma, Basosquamous (1)
Amgen (13) · BioVex Limited (6) · National Cancer Institute (NCI) (4) · H. Lee Moffitt Cancer Center and Research Institute (2) · John Rieth (2) · Memorial Sloan Kettering Cancer Center (2) · University of California, San Francisco (2) · Assistance Publique - Hôpitaux de Paris (1) · Dan Blazer III, M.D. (1) · Johns Hopkins University (1) · Jonsson Comprehensive Cancer Center (1) · Karie D. Runcie, MD (1) · M.D. Anderson Cancer Center (1) · Pfizer (1) · Provectus Biopharmaceuticals, Inc. (1)
United States (43) · France (9) · Spain (9) · United Kingdom (9) · Switzerland (8) · Belgium (7) · Canada (7) · Germany (7) · Australia (6) · Italy (6) · Greece (5) · Poland (5) · Austria (4) · Netherlands (4) · Russia (3)
John Rieth, MD (3) · Adam C Berger, MD, FACS (1) · Aleix Prat (1) · Amy J Chien, MD (1) · Andrew Hayes (1) · Bart Neyns, MD,PhD (1) · Cameron Gaskill, MD (1) · Carlos Romo, MD (1) · Christopher Barker, MD (1) · Ciara Kelly, MBBCh BAO (1) · Dan Blazer, MD (1) · Eric Wachter, Ph.D. (1) · Hatem Soliman, M.D. (1)
PMID 35115306, PMID 26014293, PMID 28923101, PMID 29561296, PMID 29896663, PMID 31171039, PMID 31971541, PMID 32633563, PMID 32669371, PMID 34132224, PMID 34330766, PMID 34519839, PMID 34627593, PMID 35927710, PMID 36113895, PMID 36648215, PMID 36759673, PMID 37621406, PMID 39673447, PMID 40156118, PMID 41271741, PMID 41698899
2014 (4), 2015 (2), UM1CA186709 (2), 2008 (1), 2018 (1), 2019 (1), P30CA016672 (1), P30CA072720 (1), U10CA180888 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186716 (1)